Study guide

18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP

Key Takeaways Explain This Topic AI

A REMS can require medication guides, certification of prescribers, pharmacies or settings, and patient monitoring; FDA removed the clozapine REMS and the autologous CAR-T REMS programs in 2025.

FDA's 2004 bar code rule requires a linear bar code containing the NDC on most prescription drug labels, which makes bar code medication administration possible.

Theft or significant loss of controlled substances must be reported to DEA within 1 business day of discovery, followed by DEA Form 106 within 45 days.

EMTALA requires a medical screening examination and stabilizing treatment or an appropriate transfer for anyone who comes to an ED, regardless of ability to pay.

Under USP <797>, administration of an immediate-use compounded sterile preparation must begin within 4 hours after preparation starts.

Last updated: October 2026

18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP

Note

Exam scope: 2025 outline subtopics 3A1 (Medication Safety, e.g., REMS, VAERS, bar codes, ISMP) and 3A3 (Healthcare Regulations and Standards, e.g., FDA, TJC, CMS, NIOSH, USP <800>). High-alert medications, automated dispensing cabinets, smart pumps, error reporting systems and hazardous drug engineering controls are covered in Section 14.1.

FDA Safety Tools

Boxed warnings : the strongest labeling warning for serious or life-threatening risks.

Drug Safety Communications : alerts about new safety findings, label changes or market actions, such as the 2025 withdrawal of andexanet alfa in the US (Section 10.1).

MedWatch : the voluntary reporting system for healthcare professionals and patients (Form 3500). Manufacturers must report adverse events they learn about (Form 3500A).

VAERS : the vaccine adverse event reporting system, run jointly by CDC and FDA. Vaccine providers must report certain events listed in the reportable events table.

Risk Evaluation and Mitigation Strategies (REMS)

FDA requires a REMS when labeling alone cannot ensure that a drug's benefits outweigh a serious risk. A REMS may include:

A Medication Guide or communication plan

Elements to assure safe use (ETASU) : certified prescribers, certified pharmacies or settings, dispensing only in certain healthcare settings, documented lab results, patient monitoring or a registry

An implementation system

REMS (examples) Key ED-relevant requirement

Extended-release buprenorphine injections Given only by healthcare providers in certified settings, never handed to patients, because IV self-injection can be fatal

  • Esketamine nasal spray Given in certified settings with observation after each dose
  • Olanzapine pamoate long-acting injection 3-hour observation for post-injection delirium/sedation syndrome

Complement C5 inhibitors (eculizumab, ravulizumab) Meningococcal vaccination and patient wallet cards; treat fever as possible meningococcemia

  • Transmucosal immediate-release fentanyl Outpatient use restricted to opioid-tolerant patients
  • Isotretinoin (iPLEDGE), mifepristone Pregnancy prevention, and certified prescribers and pharmacies

REMS programs removed in 2025: clozapine (FDA stopped expecting participation in February 2025 and eliminated the program in June 2025) and the autologous CAR-T cell therapies (June 2025). The underlying risks remain in the labeling.

ED implications: REMS-restricted products may not be stocked or orderable on short notice. Know how to obtain or substitute them, and never dispense a REMS-restricted product outside its rules.

Bar Code Medication Administration (BCMA)

FDA's 2004 bar code rule requires a linear bar code containing the National Drug Code (NDC) on most prescription drug labels and on OTC drugs commonly used in hospitals. BCMA checks the patient's wristband against the drug's bar code and the active order at the bedside, confirming the right patient, drug, dose, route and time.

In a landmark before-and-after study (Poon, 2010), BCMA with an electronic administration record reduced non-timing administration errors by about 41% and potential adverse drug events by about half.

ED barriers: verbal orders during resuscitation, overrides, bedside-prepared syringes without bar codes, and patients without wristbands.

Common workarounds that defeat BCMA: scanning a copy of the wristband taped to a computer, or scanning one vial and giving another. Pharmacy should track scanning compliance, investigate workarounds as system problems, and supply bar-coded labels for ED-prepared products.

DEA and Controlled Substances in the ED

  • Requirement Key facts
  • Ordering Schedule II drugs DEA Form 222 (single-sheet format) or electronic ordering through CSOS

Theft or significant loss Notify the DEA field office within 1 business day of discovery , then file DEA Form 106 within 45 days

Destroying expired or unwanted stock Use a reverse distributor or DEA Form 41

Wasting part of a dose Not a Form 41 event. Document it with a witness under hospital policy and audit waste against administrations to detect diversion

Diversion surveillance Analyze automated dispensing cabinet data (outlier removals, frequent overrides, late waste), resolve discrepancies promptly and investigate patterns

Buprenorphine for opioid use disorder The X-waiver was eliminated in December 2022 ; any practitioner with a Schedule III registration can prescribe. New and renewing registrants must complete 8 hours of substance use disorder training (MATE Act)

"Three-day rule" (21 CFR 1306.07(b)) Practitioners without a narcotic treatment program registration may dispense up to a 3-day supply at one time of buprenorphine or methadone to relieve acute withdrawal while arranging treatment (DEA final rule, August 2023)

CMS Conditions of Participation and EMTALA

Hospitals must meet the Medicare Conditions of Participation (CoPs) to bill Medicare. Accreditation by The Joint Commission or another approved accreditor confers "deemed status."

42 CFR 482.25 (Pharmaceutical services): pharmacy directed by a qualified pharmacist; drugs stored securely; expired drugs removed from use; drug administration errors, adverse reactions and incompatibilities reported; controlled-substance abuses and losses reported; drug information available to staff.

42 CFR 482.23(c): drugs are given according to orders from authorized practitioners. Verbal orders are used rarely and authenticated promptly.

Standing orders (42 CFR 482.24): allowed when approved by the medical staff, nursing and pharmacy, based on evidence, and documented and authenticated in the record. Examples include anaphylaxis, hypoglycemia and triage protocols.

EMTALA (Emergency Medical Treatment and Labor Act, 1986)

EMTALA applies to Medicare-participating hospitals with emergency departments. Anyone who comes to the ED requesting care must receive:

A medical screening examination to determine whether an emergency medical condition exists, regardless of insurance or ability to pay . Insurance questions must not delay screening or treatment.

Stabilizing treatment , or an appropriate transfer : the receiving hospital accepts the patient, records go with the patient, transport is qualified, and the physician certifies that the benefits of transfer outweigh the risks.

For the pharmacist, needed emergency drugs cannot be withheld or delayed because of cost or coverage.

The Joint Commission: 2026 National Performance Goals

Under Accreditation 360 (effective January 1, 2026), the National Patient Safety Goals were replaced by 14 National Performance Goals . Goal 14 covers medication management:

Standard Key elements of performance

NPG.14.01.01 Pharmaceutical services When the pharmacy is not open 24/7, a qualified professional reviews orders and a pharmacist reviews them retrospectively. The hospital sets a policy for which automated dispensing cabinet overrides are reviewed and how often; reviewing 100% of overrides is not required

NPG.14.02.01 Selection and procurement Standardize and limit drug concentrations ; communicate shortages and outages; follow written substitution protocols

NPG.14.03.01 Labeling in procedural settings Label every medication and solution on and off the sterile field unless it is immediately administered

NPG.14.04.01 Anticoagulation Approved protocols for reversal and bleeding management ; perioperative plans; use oral unit-dose, prefilled syringe or premixed products when available

NPG.14.05.01 Medication information Collect the home medication list (the hospital defines what to collect in the ED), reconcile discrepancies, and give patients written medication information at discharge

NPG.14.06.01 Antibiotic stewardship A multidisciplinary committee; track use as days of therapy per 1,000 days present, or report to NHSN

Other goals relevant to ED pharmacy include Goal 1 (correct patient identification and communication of critical results), Goal 4 (assessment of health-related social needs, Section 18.3), Goal 6 (pain management and safe opioid prescribing, including prescriber and pharmacist access to the prescription drug monitoring program) and Goal 8 (reducing suicide risk). The Sentinel Event Policy still expects a comprehensive systematic analysis and action plan after a sentinel event (Section 14.1).

Under long-standing Joint Commission medication management standards, a pharmacist prospectively reviews medication orders. The exceptions are when a licensed practitioner controls ordering, preparation and administration, or when a delay would harm the patient in an urgent situation. These exceptions cover much of resuscitation care.

NIOSH, USP <800> and USP <797>

NIOSH List of Hazardous Drugs in Healthcare Settings (2024): reorganized into two tables . Table 1 lists drugs that carry manufacturer special handling information or meet the definition of a carcinogen; Table 2 lists other hazardous drugs. ED examples include methotrexate, misoprostol and several antiseizure and hormonal drugs.

USP <800> sets containment, PPE and handling requirements for hazardous drugs (Section 14.1). It is enforceable when adopted by a state or board of pharmacy. An assessment of risk allows alternative containment for some dosage forms that are not antineoplastic.

USP <797> (2023 revision) immediate-use compounded sterile preparations:

May be prepared outside a cleanroom using aseptic technique.

May involve no more than 3 different sterile products .

Administration must begin within 4 hours after preparation starts .

Must be labeled unless the person who prepared it administers it immediately.

Examples include bedside dilution of push-dose vasopressors and reconstitution of emergency antibiotics.

ISMP Safe Practice Guidelines for adult IV push medications: use commercially available ready-to-administer products when possible, do not dilute unless the label or a protocol requires it, never draw medication from a prefilled syringe into another syringe , and label every syringe that is not immediately administered.